Company Encyclopedia
View More
name
GRANDPHARMA
00512.HK
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage.
1.450 T
00512.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking6/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.65%B
    • Profit Margin17.77%A
    • Gross Margin58.95%B
  • Growth ScoreB
    • Revenue YoY10.56%B
    • Net Profit YoY-13.67%D
    • Total Assets YoY6.29%B
    • Net Assets YoY8.76%B
  • Cash ScoreB
    • Cash Flow Margin562.89%C
    • OCF YoY10.56%B
  • Operating ScoreC
    • Turnover0.46C
  • Debt ScoreB
    • Gearing Ratio34.67%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Understanding the Market | GRANDPHARMA rose over 6% in the morning as the new myopia drug GPN00884 recently started its Phase IIa clinical trial in China

    GRANDPHARMA rose over 6% in the morning, and as of the time of writing, it has increased by 6.42%, trading at HKD 8.79, with a transaction volume of HKD 101 million. In terms of news, GRANDPHARMA recently announced that the global innovative ophthalmic drug GPN00884, used to delay the progression of myopia in children, has completed the enrollment and dosing of the first patient in its Phase IIa clinical study in China. This means that GPN00884 will enter an important phase to explore drug dosage and assess preliminary efficacy. If the expected drug effectiveness is successfully realized, clinical practice may welcome a new solution for alleviating the progression of myopia in children. It is worth noting that in July of this year, the oxymetazoline hydrochloride nasal spray (OC-01) was launched in mainland China, revolutionizing the treatment experience for dry eye patients through nasal spray. Recently, GRANDPHARMA successfully held a national launch conference for OC-01, taking advantage of the 11th Global Dry Eye Academic Conference themed "Caring for Dry Eye Patients, Welcoming the Era of Native Tears - 2025 New Advances in Dry Eye Diagnosis and Treatment and the Construction of Ocular Surface Health Ecology," officially announcing the arrival of a new era in dry eye treatment from "external replacement" to "internal awakening."

    Zhitong·
    HK
    00512
    -0.61%
    Zhitong·
    HK
    00512
    -0.61%

    GRANDPHARMA leads a new era in dry eye treatment with the successful national launch of the world's first dry eye nasal spray OC-01

    GRANDPHARMA successfully held the national launch conference for OC-01 at the 11th Global Dry Eye Academic Conference, marking a new era in the treatment of dry eye disease. The OC-01 nasal spray innovates the treatment experience for dry eye patients by promoting the secretion of natural tears. This conference brought together multiple ophthalmology experts to discuss the current status and future of dry eye prevention and treatment, emphasizing the importance of eye health issues on the quality of life of the population

    Zhitong·
    HK
    00512
    -0.61%
    Zhitong·
    HK
    00512
    -0.61%

    GRANDPHARMA: The Phase IIa clinical study of the global innovative ophthalmic drug GPN00884 has completed the enrollment of its first patient in China

    GRANDPHARMA announced that the first patient has been enrolled in the Phase IIa clinical study of its global innovative ophthalmic drug GPN00884 in China. The study aims to evaluate the efficacy and safety of GPN00884 eye drops in slowing the progression of myopia in children, with plans to recruit 80 myopic patients aged 6 to 12 years. GPN00884 has a new mechanism that avoids the side effects of low-concentration atropine, meeting the clinical needs for the treatment of myopia in children in China. This study marks an important advancement for the company in the field of ophthalmology

    Zhitong·
    HK
    00512
    -0.61%
    Zhitong·
    HK
    00512
    -0.61%

    Chairman Tang Weikun increased his holdings in GRANDPHARMA by 50,000 shares at a price of HKD 8.21 per share

    According to the latest information from the Hong Kong Stock Exchange, on October 13th, Chairman Tang Weikun increased his holdings in GRANDPHARMA by 50,000 shares at a price of HKD 8.21 per share, totaling HKD 410,500. After the increase, the latest number of shares held is 950,000, with a latest holding ratio of 0.03%

    Zhitong·
    HK
    00512
    -0.61%
    Zhitong·
    HK
    00512
    -0.61%

    GRANDPHARMA aXess demonstrates globally leading revolutionary potential, accelerating global innovation layout and advancing the "Go Global" strategy

    GRANDPHARMA's globally innovative artificial blood vessel product aXess has achieved success in critical clinical trials, demonstrating safety and efficacy superior to current standard therapies. This breakthrough is expected to provide a safer and more effective hemodialysis treatment option for patients with end-stage renal disease (ESRD), marking an important milestone for GRANDPHARMA in the field of precision interventional diagnosis and treatment for cardiovascular and cerebrovascular diseases. It is estimated that by 2030, the number of ESRD patients worldwide will increase to nearly 14.61 million, with Chinese patients accounting for over 30%

    Zhitong·
    HK
    00512
    -0.61%
    Zhitong·
    HK
    00512
    -0.61%
    © 2025 Longbridge｜Disclaimer